Overview
Current Appointments & Affiliations
Robert Machemer M.D. Distinguished Professor of Ophthalmology
·
2013 - Present
Ophthalmology, Vitreoretinal Diseases & Surgery,
Ophthalmology
Professor of Ophthalmology
·
1998 - Present
Ophthalmology, Vitreoretinal Diseases & Surgery,
Ophthalmology
Chief, Division of Retinal Ophthalmology
·
2008 - Present
Ophthalmology, Vitreoretinal Diseases & Surgery,
Ophthalmology
Recent Publications
Best Practices for High-Quality Anterior Segment Optical Coherence Tomography Imaging of Eyes with the Port Delivery Platform Implant.
Journal Article Diagnostics (Basel) · December 5, 2025 Background/Objectives: Anterior segment optical coherence tomography (AS-OCT) is a non-invasive imaging modality used to evaluate anterior segment features. This report aims to inform clinicians of best practices to obtain high-resolution AS-OCT images of ... Full text Link to item CiteIMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS.
Journal Article Retina · November 1, 2025 BACKGROUND/PURPOSE: To assess the effects of faricimab versus aflibercept on epiretinal membrane (ERM) formation in eyes with diabetic macular edema. METHODS: Post hoc analysis of phase 3 YOSEMITE/RHINE trial data in eyes with diabetic macular edema receiv ... Full text Link to item CiteRecent Grants
A Ph 4, Multicenter, Open-label Study to Evaluate Long-term Safety and Efficacy of Revakinagene Taroretcel-Lwey (NT-501) Previously Implanted in a Ph 1, Ph 2, or Ph 3 Clinical Study and to Evaluate NT-501 Implanted in Participants...
ResearchPrincipal Investigator · Awarded by Neurotech Pharmaceuticals, Inc. · 2025 - 2030A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment- Experienced Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD)
ResearchPrincipal Investigator · Awarded by Adverum Biotechnologies, Inc · 2022 - 2029Ora_Sepul_DRC Ph3 Study of Sepofarsen in Subjects with Leber Congential Amaurosis (LCA)_HYPERION
ResearchPrincipal Investigator · Awarded by Ora LLC · 2024 - 2029View All Grants
Education, Training & Certifications
University of California San Francisco, School of Medicine ·
1983
M.D.